Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 51 to 75 of 903

TitleReference numberPublishedLast updated
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Sparsentan for treating primary IgA nephropathyTA1074
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096
Tirzepatide for managing overweight and obesityTA1026
Tirzepatide for treating type 2 diabetesTA924
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and overTA1093
Guselkumab for treating moderately to severely active ulcerative colitisTA1094
Guselkumab for previously treated moderately to severely active Crohn's diseaseTA1095
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090

Results per page

  1. 10
  2. 25
  3. 50
  4. All